Association of Fatal Myocardial Infarction with Past Level of Physica
Activity

A pooled analysis of cohort studies

**Supplementary Material** 

# Table of contents

Appendix Tables	3
Appendix Table 1: Study characteristics of the 10 participating European cohorts	3
Appendix Table 2: Pooled baseline characteristics for patients with MI, by level of PA	4
Appendix Table 3: Pooled ORs, 95% CIs, and I <sup>2</sup> statistics for fixed- and random-effects multivariate mo	odels 5
Appendix Table 4: Pooled ORs, 95% Cis, and I <sup>2</sup> statistics for fixed- and random-effects network meta-a	•
Appendix Table 5: Assessment of PA, by individual cohort	7
Appendix Table 6: No. of outcomes, by individual cohort and level of physical activity	8
Appendix Table 7: Post-hoc analysis of pooled ORs, 95% CIs, and I <sup>2</sup> statistics, by selected cohort characteristics	9
Appendix Figures	10
Appendix Figure 1: Comparison-adjusted funnel plots	10
Appendix Figure 2: Flow diagram summarizing the derivation of the study population	11
Appendix Text	12
Standardisation of physical activity level	12

# **Appendix Tables**

## Appendix Table 1: Study characteristics of the 10 participating European cohorts

Cohort	Country	Brief description	Recruitment period	Follow- up, years	Total number of participants	Total number of MI during follow-up (fatal outcome at 28 days)
ATTICA	Greece	Participants >18 years and residing in the Attica region within the greater Athens area.	2001-02	10	3042	177 (69)
BELSTRESS	Belgium	Participants aged 35-59 years, who were workers from 25 companies in Belgium.	1994-98	1	13 897	39 (17)
CCHS	Denmark	A random draw from the Danish Civil Registration System of participants aged 20-93 years and residing in Østerbro.	1976-78	34	14 223	1664 (647)
CGPS	Denmark	A random draw from the Danish Civil Registration System of participants aged 20-93 years and residing in Herlev and Østerbro.	2003-14	1-11	104 801	1401 (161)
CONOR	Norway	Consisting of 10 population surveys of adults: Tromsø IV, HUNT II, HUSK, Oslo II, HUBRO, OPPHED, Tromsø V, I-HUBRO, TROFINN, MoRo II.	1994-2003	Ongoing	173 236	9120 (1917)
CRPH	Denmark	Consisting of 5 combined cohorts: MONICA I, II and III, Inter99, and Health 2006. Random samples of the general population in up to 11 municipalities in the greater Copenhagen area.	1982-2008	Ongoing	17 571	778 (95)
MORGEN- project	The Netherlan ds	A random sample of participants aged 20-65 years in three towns in the Netherlands (Amsterdam, Doetinchem, Maastricht).	1993-97	13-17	17 888	337 (53)
Million Women Study	United Kingdom	Recruitment of one in every four UK women born in 1935-50 at 66 NHS breast screening centres.	1996-2001	Ongoing	632 177	10 451 (1509)
Rotterdam study	The Netherlan ds	Participants aged ≥40 years residing in the Ommord district of Rotterdam.	1990-	Ongoing	14 926	384 (87)
UK Biobank	United Kingdom	Participants 40-69 years of age from the general population.	2006-10	Ongoing	502 536	3789 (421)

# Appendix Table 2: Pooled baseline characteristics for patients with MI, by level of PA

Level of physical activity								
	Sedentary	Low	Moderate	High				
No. Patients	5504	5654	5628	11 354				
Demographics:								
Age, years	69.1 (11.6)	68.4 (10.5)	67.7 (10.1)	68.9 (7.5				
Males, %	59.3	59.4	54.0	22.0				
Risk factors:								
Diabetes mellitus, %	27.6	18.2	13.6	8.5				
Arterial hypertension, %	57.7	51.0	47.2	39.2				
Family history of CVD, %	50.2	49.1	48.9	51.3				
Active smoking, %	43.0	41.7	39.8	48.5				
Biometrics:								
Body-mass index [kg/m <sup>2</sup> ]	27.6 (4.5)	26.9 (4.1)	26.9 (4.2)	26.7 (4.5				
Total cholesterol [mmol/L]	6.4 (1.3)	6.4 (1.3)	6.2 (1.1)	6.0 (1.2				
Systolic blood pressure [mmHg]	147.3 (22.7)	145.8 (21.2)	144.9 (20.6)	145.4 (19.6				
Diastolic blood pressure [mmHg]	83.8 (12.3)	84.6 (12.0)	84.1 (11.5)	83.6 (10.8)				
Time from baseline to MI:								
>5 years, %	67.7	68.6	68.8	70.8				

# Appendix Table 3: Pooled ORs, 95% CIs, and I<sup>2</sup> statistics for fixed- and random-effects multivariate models

			Level of phy Fixed-effects				Random-eff	acts models			
	Number of cohorts	Number of patients (events)	Sedentary	Low	Moderate	High	Sedentary	Low	Moderate	High	l², %
nstant fatal MI											
Unadjusted	10	28 140 (3101)	1	0.86 (0.76-0.97)	0.72 (0.63-0.81)	0.63 (0.55-0.72)	1	0.83 (0.70-0.98)	0.69 (0.58-0.82)	0.61 (0.51-0.73)	18.3
Adjustment											
Age and sex	9	27 798 (3055)	1	0.82 (0.73-0.93)	0.73 (0.64-0.82)	0.62 (0.53-0.71)	1	0.74 (0.59-0.93)	0.65 (0.52-0.82)	0.56 (0.44-0.70)	44.5
Age, sex, and CVD risk factors	6	26 602 (2990)	1	0.85 (0.75-0.97)	0.76 (0.66-0.87)	0.65 (0.54-0.79)	1	0.76 (0.59-0.97)	0.67 (0.52-0.86)	0.58 (0.44-0.77)	49.0
Age, sex, CVD risk factors, alcohol consumption, smoking, and socioeconomic status	6	26 602 (2990)	1	0.90 (0.78-1.03)	0.77 (0.66-0.90)	0.63 (0.50-0.80)	1	0.79 (0.60-1.04)	0.67 (0.51-0.89)	0.55 (0.40-0.76)	47.3
28-day fatal MI											
Unadjusted	7	24 618 (1868)	1	0.82 (0.72-0.94)	0.61 (0.53-0.71)	0.66 (0.56-0.78)	1	0.86 (0.71-1.03)	0.64 (0.52-0.77)	0.67 (0.55-0.83)	24.9
Adjustment											
Age and sex	6	24 256 (1808)	1	0.78 (0.68-0.90)	0.63 (0.54-0.73)	0.66 (0.56-0.79)	1	0.78 (0.68-0.90)	0.63 (0.54-0.73)	0.66 (0.56-0.79)	<0.1
Age, sex, and CVD risk factors	6	24 256 (1808)	1	0.78 (0.67-0.90)	0.64 (0.54-0.75)	0.69 (0.56-0.84)	1	0.78 (0.67-0.90)	0.64 (0.54-0.75)	0.69 (0.56-0.84)	<0.1
Age, sex, CVD risk factors, lcohol consumption, smoking, nd socioeconomic status	4	19 736 (1334)	1	0.85 (0.71-1.03)	0.64 (0.51-0.80)	0.72 (0.51-1.00)	1	0.85 (0.71-1.03)	0.64 (0.51-0.80)	0.72 (0.51-1.00)	<0.

# Appendix Table 4: Pooled ORs, 95% Cis, and I<sup>2</sup> statistics for fixed- and random-effects network meta-analysis

Appendix Table 4	Pooled odd	s ratios, 95% confide	nce intervals	s, and I <sup>2</sup> statis	stics for fixed-	and random-effe	cts ne	twork	meta-anal	ysis
			Level of phys	sical activity			Heterogeneity			
	Number of cohorts	Number of patients (events)	Sedentary	Low	Moderate	High	Q	d.f.	p-value	l², %
Instant fatal MI										
FE model	10	28 140 (3101)	1	0.86 (0.76-0.97)	0.72 (0.63-0.81)	0.63 (0.55-0.72)	-	-	-	-
RE model	10	28 140 (3101)	1	0.84 (0.76-1.01)	0.68 (0.56-0.83)	0.59 (0.47-0.72)	32.6	26	0.17	20.2
28-day fatal MI										
FE model	7	24 618 (1868)	1	0.82 (0.72-0.94)	0.61 (0.53-0.71)	0.66 (0.56-0.78)	-	-	-	-
RE model	7	24 618 (1868)	1	0.84 (0.68-1.03)	0.65 (0.53-0.81)	0.65 (0.52-0.83)	25.1	18	0.12	28.2
FE, fixed-effects. RE,	random-effec	ts.								

# Appendix Table 5: Assessment of PA, by individual cohort

Appendix Table 5	Assessment of p	hysical activity,	by individua	l cohort			
			Assessment	of physical activity			
Cohort	Country	Recruitment period	Method	No. of items	Time fran	ne	
					1 week	4 weeks	1 year
ATTICA	Greece	2001-02	SRQ	7	Х		
Belstress	Belgium	1994-98	SRQ	1	Х		
CCHS	Denmark	1976-78	SRQ	1			Х
CGPS	Denmark	2003-14	SRQ	1			Х
CONOR	Norway	1994-2003	SRQ	2			Х
CRPH	Denmark	1982-2008	SRQ	5	Х		
MWS	United Kingdom	1996-2001	SRQ	2	Х		
MORGEN-Project	The Netherlands	1993-97	SRQ	3			Х
Rotterdam study	The Netherlands	1990-	SRQ	28	Х		
UK Biobank	United Kingdom	2006-10	SRQ	11		Х	
SRQ, self-reported of	questionnaire						

## Appendix Table 6: No. of outcomes, by individual cohort and level of physical activity

Sedentary	Low			
		Moderate	High	Total
5504	5654	5628	11 354	28 14
47/109	9/21	4/16	9/31	69/17
4/11	10/19	3/9	0/0	17/3
111/346	227/898	83/398	4/22	425/166
13/110	43/707	36/511	3/73	95/140
546/3896	299/2332	240/2129	75/763	1160/912
5/208	12/424	4/141	0/5	21/77
46/255	84/606	193/1585	897/8005	1220/10 4
1/7	3/14	0/32	42/284	46/33
1/4	3/12	2/26		27/38
3/558	11/621	1/781	6/1829	21/378
777/5504	701/5654	566/5628	1057/11 354	3101/28 14
				N
				N
	•	•		225/12
•	•	•	•	66/130
392/3350	200/2033	120/1889	46/688	758/79
25/203	32/412	17/137	0/5	74/7!
9/209	25/522	36/1392	219/7108	289/92
0/6	0/11	1/32	6/242	7/29
2/3	3/9	5/24	50/321	60/3
65/555	65/610	79/780	191/1823	400/370
547/4658	487/4932	326/5044	519/10 275	1879/24 90
NA	NA	NA	NA	N
NA	NA	NA	NA	N
NA	NA	NA	NA	N
NA	NA	NA	NA	N
449/3896	237/2332	199/2129	58/763	943/91
	27/424	11/141		52/7
•	106/606	242/1585	•	1562/10 4
NA	NA	NA	NA	N
				131/3
NA NA	NA	NA	NA NA	N
E10//262	270/2274	AC2 /2001	1220/0115	2688/20 7
	4/11 111/346 13/110 546/3896 5/208 46/255 1/7 1/4 3/558 777/5504  NA NA 48/235 6/97 392/3350 25/203 9/209 0/6 2/3 65/555 547/4658  NA	4/11 10/19 111/346 227/898 13/110 43/707 546/3896 299/2332 5/208 12/424 46/255 84/606 1/7 3/14 1/4 3/12 3/558 11/621  777/5504 701/5654  NA NA NA 48/235 129/671 6/97 33/664 392/3350 200/2033 25/203 32/412 9/209 25/522 0/6 0/11 2/3 3/9 65/555 65/610  547/4658 487/4932  NA N	4/11 10/19 3/9  111/346 227/898 83/398  13/110 43/707 36/511  546/3896 299/2332 240/2129  5/208 12/424 4/141  46/255 84/606 193/1585  1/7 3/14 0/32  1/4 3/12 2/26  3/558 11/621 1/781  777/5504 701/5654 566/5628  NA NA NA NA  48/235 129/671 44/315  6/97 33/664 24/475  392/3350 200/2033 120/1889  25/203 32/412 17/137  9/209 25/522 36/1392  0/6 0/11 1/32  2/3 3/9 5/24  65/555 65/610 79/780  547/4658 487/4932 326/5044  NA NA NA NA  NA NA NA  NA NA NA  NA NA  NA NA  NA NA  NA NA  NA NA  NA NA  NA NA  NA	4/11       10/19       3/9       0/0         111/346       227/898       83/398       4/22         13/110       43/707       36/511       3/73         546/3896       299/2332       240/2129       75/763         5/208       12/424       4/141       0/5         46/255       84/606       193/1585       897/8005         1/7       3/14       0/32       42/284         1/4       3/12       2/26       21/342         3/558       11/621       1/781       6/1829         777/5504       701/5654       566/5628       1057/11 354         NA       NA       NA       NA         NA       NA       NA       NA         NA       NA       NA       NA         48/235       129/671       44/315       4/18         6/97       33/664       24/475       3/70         392/3350       200/2033       120/1889       46/688         25/203       32/412       17/137       0/5         9/209       25/522       36/1392       219/7108         0/6       0/11       1/32       6/242         2/3       3/9

BELSTRESS, Belgian Job Stress Study. CCHS, Copenhagen City Heart Study. CGPS, Copenhagen General Population Study. CONOR, Cohort of Norway. CRPH, Cohort of the Research for Prevention and Health. MI, myocardial infarction. MORGEN-project, Monitoring Risicofactoren en Gezondheid in Nederland. UK Biobank, United Kingdom Biobank. \* Included all out-of-hospital deaths in the study populations regardless of cause.

# Appendix Table 7: Post-hoc analysis of pooled ORs, 95% CIs, and I<sup>2</sup> statistics, by selected cohort characteristics


	Number of cohorts	Number of patients (events)	Level of physical activity				
			Sedentary	Low	Moderate	High	- l², %
Region							
Scandinavia	4	12 958 (1701)	1	0.71 (0.51-0.98)	0.66 (0.47-0.92)	0.56 (0.38-0.84)	64.4
Other European	5	14 840 (1354)	1	0.81 (0.58-1.15)	0.60 (0.43-0.82)	0.54 (0.40-0.72)	< 0.1
Recruitment period <sup>a</sup>							
<1990	3	2821 (473)	1	0.69 (0.53-0.90)	0.53 (0.38-0.74)	0.31 (0.15-0.64)	< 0.1
1990-2000	2	9159 (1177)	1	0.87 (0.75-1.02)	0.84 (0.71-0.99)	0.71 (0.54-0.93)	< 0.1
>2000	4	15 818 (1405)	1	0.66 (0.46-0.95)	0.55 (0.39-0.78)	0.49 (0.35-0.68)	14.2
Information on prior heart failure							
Yes	6	23 197 (2996)	1	0.68 (0.53-0.88)	0.61 (0.47-0.79)	0.53 (0.41-0.69)	60.1
No	3	4601 (59)	1	1.64 (0.77-3.46)	0.88 (0.32-2.45)	0.39 (0.13-1.23)	< 0.1
Proportion of cohort in high PA group							
<40%	6	13 174 (1787)	1	0.71 (0.53-0.94)	0.65 (0.48-0.88)	0.55 (0.38-0.79)	50.4
≥40%	3	14 624 (1268)	1	0.83 (0.57-1.20)	0.61 (0.44-0.86)	0.55 (0.40-0.75)	< 0.1
Prevalence of instant fatal MI							
<10%	4	6347 (164)	1	0.83 (0.37-1.89)	0.73 (0.31-1.72)	0.29 (0.12-0.74)	55.3
≥10%	5	21 451 (2891)	1	0.75 (0.60-0.95)	0.67 (0.53-0.84)	0.59 (0.46-0.75)	52.7


# **Appendix Figures**

#### Appendix Figure 1: Comparison-adjusted funnel plots

**Appendix Figure 1** Comparison-adjusted funnel plots displaying the natural logarithms of odds ratios against their SEs for (A) instant and (B) 28-day fatal MI, respectively.

Dots represent study-specific comparisons: black = low vs. sedentary; red = moderate vs. sedentary; blue = high vs. sedentary; dark grey = moderate vs. low; grey = high vs. low; light grey = high vs. moderate.






#### Appendix Figure 2: Flow diagram summarizing the derivation of the study population

**Appendix Figure 2** Flow diagram summarizing the derivation of the study population.

Please note that a participant may meet more than one exclusion criteria.



## **Appendix Text**

#### Standardisation of physical activity level

Current guidelines recommend that healthy adults of all ages engage in at least 150 minutes of moderate intensity or 75 minutes a week of vigorous intensity PA or an equivalent combination thereof; for additional benefit these durations may be doubled (10). This confers with approximate minimum values of weekly net energy expenditure of 7.5 to 14.75 MET-hrs, or 15 to 29.5 MET-hrs, respectively.

Intensity of PA	IPAQ-based conversion rule
Walking (MET-min/week)	3.3 x minutes of walking x walking days
Moderate (MET-min/week)	4.0 x minutes of moderate intensity activity x moderate intensity activity days
Vigorous (MET-min/week)	8.0 x minutes of vigorous intensity activity x vigorous intensity activity days
Cumulative PA (MET-hrs per week)	(Walking MET-min/week + Moderate MET-min/week + Vigorous MET-min/week) / 60 min/hrs
IPAQ, International Physical Activity Q	uestionnaire. MET, metabolic equivalents. PA, physical activity

Applying the above conversion algorithm to the categorization of leisure-time PA used in the Copenhagen City Heart Study (21,23):

CCHS PA category	IPAQ-based calculation
Inactive or light physical activity <2	(3.3 x 120 minutes x 1 day) / 60 min/hrs ≈
hours per week	7 MET-hrs/week
Light physical activity 2-4 hours per	(4.0 x (120 to 240 minutes x 1 day) / 60 min/hrs ≈
week	7 to 16 MET-hrs/week
Light activity >4 hours per week or	(4.0 x (>240 minutes x 1 day) / 60 min/hrs ≈
strenuous activity 2-4 hours per week	> 16 MET-hrs/week
	(8.0 x (120 to 240 minutes x 1 day) / 60 min/hrs ≈
	16 to 32 MET-hrs/week
Strenuous activity >4 hours per week	(8.0 x (>240 minutes x 1 day) / 60 min/hrs ≈
or hard training	> 32 MET-hrs/week
IPAQ, International Physical Activity Que	stionnaire. MET, metabolic equivalents. PA, physical activity

These cut-off values are in excellent agreement with those stated in the 2016 European Guidelines of Cardiovascular Prevention in Clinical Practice (10) as shown above.